Liposomal latanoprost

Liposomal latanoprost is an extended release drug delivery solution for glaucoma and is a ground breaking development in nanomedicine.

Liposomal latanoprost has completed a pilot Phase 2a trial. Although the trial was completed at 3 months, patients within the trial were monitored beyond the study period.

All the patients who were previously on prostaglandin medication still showed a clinically significant ocular hypotensive effect after 6 months from injection.

Publications

About Glaucoma

Glaucoma is the leading cause of irreversible blindness worldwide. Intraocular pressure (IOP) is the major risk factor for glaucoma. Medical therapy with topical eyedrops to lower the IOP remains as the first line treatment to prevent progressive visual field loss and blindness.[1] As the number of elderly in the world rapidly increases, glaucoma morbidity will rise. It has been estimated that glaucoma will be the most common cause of blindness in the world this century with almost 70 million cases of glaucoma worldwide.[2] This figure has very important public health implications for a condition which causes irreversible blindness, that typically affects the working population.

Medical treatment with eyedrops is often lifelong. Like any chronic treatment, eyedrops require patient adherence as well as correct application. Unfortunately many patients have trouble using eyedrops and applying them correctly in the eye at the correct time. A consequence of poor patient adherence is treatment failure and a poor outcome from disease progression.[3] It is estimated that at least 10% of blindness is directly attributed to poor patient adherence to prescribed medications.[4]

Here at Peregrine, we recognize and understand the challenges faced by the ophthalmologist and their patients. Our goal is to provide solutions to improve glaucoma management.

References

  1. Quigley HA, Broman AT. Br J Ophthalmol 2006; 90: 262-7.
  2. Foster PJ, et al. Arch Ophthalmol. 2000;118:1105-11.
  3. Robin AL, et al. Am J Ophthal. 2007;144:533-40.
  4. Tsai JC, et al. J of Glaucoma. 2003;12:393-8.

Pipeline

Liposomal delivery systems for other classes of anti-glaucoma drugs are currently being developed.